T-cell engagers (TCEs) are among the most promising new modalities in cancer therapy, but limitations in efficacy and safety have been barriers to realizing their potential for solid tumor indications. Data shown here illustrate that we can repeatedly generate TCEs that show potent tumor-cell killing without excessive cytokine release in vitro across multiple tumor targets.